Saizen + Saizen

ApprovedCompleted
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Growth Hormone Deficiency

Conditions

Growth Hormone Deficiency, Turner Syndrome

Trial Timeline

May 31, 2005 → Sep 30, 2007

About Saizen + Saizen

Saizen + Saizen is a approved stage product being developed by Merck for Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT00256126. Target conditions include Growth Hormone Deficiency, Turner Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00256126ApprovedCompleted

Competing Products

20 competing products in Growth Hormone Deficiency

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
HER3-DXdDaiichi SankyoPre-clinical
23
ErlotinibAstellas PharmaPhase 2
52
radio-labeled naquotinib + naquotinibAstellas PharmaPhase 1
33
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
Somatropin + SomatropinEli LillyPhase 3
77
Somatropin + SomatropinEli LillyPhase 3
77
somatropin, rDNA origin, for injectionEli LillyPhase 3
77
Sterile becaplermin gel vs. sterile placebo gel treatment 1Johnson & JohnsonPre-clinical
23
ABT-414AbbViePre-clinical
23
Saizen® A + Saizen® BMerckPhase 3
77
Saizen® solution for injection (referred as Saizen®)MerckApproved
85
Cetuximab + FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)MerckPhase 3
77
MiransertibMerckPhase 2
52
MiransertibMerckPhase 1/2
41
ARX201 + ARX201 + ARX201MerckPhase 2
52